Healthcare of Ontario Pension Plan Trust Fund Acquires 15,527 Shares of Corteva, Inc. $CTVA

Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of Corteva, Inc. (NYSE:CTVA) by 58.1% during the first quarter, HoldingsChannel reports. The firm owned 42,239 shares of the company’s stock after purchasing an additional 15,527 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Corteva were worth $3,536,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Drummond Knight Asset Management Pty Ltd acquired a new position in shares of Corteva during the fourth quarter worth about $25,713,000. Arbejdsmarkedets Tillaegspension acquired a new stake in shares of Corteva in the fourth quarter valued at about $23,679,000. Leonteq Securities AG purchased a new stake in shares of Corteva during the 4th quarter valued at about $2,350,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Corteva by 23.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,075 shares of the company’s stock valued at $7,378,000 after buying an additional 20,957 shares during the period. Finally, Brandes Investment Partners LP lifted its position in Corteva by 1.1% during the 4th quarter. Brandes Investment Partners LP now owns 2,312,515 shares of the company’s stock worth $155,009,000 after acquiring an additional 24,985 shares in the last quarter. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Quarterly earnings exceeded expectations: Corteva reported second-quarter EPS of $2.30, above the $2.24 consensus estimate and up from $2.20 a year earlier. Corteva Q2 Earnings Beat Estimates
• Positive Sentiment: Full-year outlook was raised: Management increased its 2026 EPS guidance to $3.60-$3.80, reflecting strong first-half performance, cost controls and growth from strategic platforms. The midpoint is broadly consistent with analyst expectations. Corteva Delivers Strong First Half and Raises Outlook
• Positive Sentiment: Growth initiatives remain supportive: Demand for newer seed germplasm, trait technologies and crop-protection products, along with licensing growth and operational improvements, helped offset competitive pricing pressure. Corteva also remains on schedule for the planned October 1 Vylor spin-off. Why Corteva’s Seed and Crop Protection Engines Matter
• Neutral Sentiment: Separation could reshape the investment story: Corteva’s innovation pipeline, including crop-protection products and royalty opportunities, may support future growth after the planned business split, although the benefits will depend on execution. Corteva’s Innovation Pipeline
• Negative Sentiment: Revenue missed expectations: Second-quarter revenue was $6.38 billion, below the $6.60 billion analyst estimate, and declined 1.2% year over year. Competitive pricing remains a concern. Corteva Earnings Press Release
• Negative Sentiment: Valuation and execution risks are elevated: After a powerful rally, CTVA trades near its 52-week high at a premium earnings multiple. Investors may remain cautious about separation costs, execution risk and whether growth can justify the valuation. Is CTVA Stock Worth Buying After Its Rally?

Corteva Trading Down 1.2%

NYSE:CTVA opened at $89.39 on Friday. The company has a market cap of $59.79 billion, a PE ratio of 52.58, a P/E/G ratio of 2.74 and a beta of 0.56. The business’s 50 day moving average is $82.16 and its two-hundred day moving average is $79.55. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07. Corteva, Inc. has a 52 week low of $60.53 and a 52 week high of $90.97.

Corteva (NYSE:CTVA) last issued its quarterly earnings results on Thursday, July 30th. The company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.06. The business had revenue of $6.38 billion during the quarter, compared to the consensus estimate of $6.60 billion. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The business’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.20 EPS. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. On average, analysts predict that Corteva, Inc. will post 3.76 EPS for the current year.

Corteva Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be paid a dividend of $0.18 per share. The ex-dividend date is Tuesday, September 1st. This represents a $0.72 annualized dividend and a yield of 0.8%. Corteva’s payout ratio is presently 42.35%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CTVA. Weiss Ratings upgraded Corteva from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, May 7th. BNP Paribas Exane boosted their target price on shares of Corteva from $74.00 to $77.00 in a research report on Wednesday, May 6th. Mizuho upped their target price on shares of Corteva from $96.00 to $97.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Rothschild & Co Redburn raised their price target on shares of Corteva from $80.00 to $90.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, UBS Group dropped their price target on shares of Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $90.19.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.